
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Remove Australian Register of Therapeutic Goods (ARTG) filter Australian Register of Therapeutic Goods (ARTG) (1)
- Remove Biologicals filter Biologicals (2)
- Remove Blood and blood components filter Blood and blood components (0)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Remove Manufacturing filter Manufacturing (1)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (6) Apply Prescription medicines filter
- Remove Safety of medicines & medical devices filter Safety of medicines & medical devices (0)
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Australian Register of Therapeutic Goods (ARTG) filter Australian Register of Therapeutic Goods (ARTG)
- (-) Remove Biologicals filter Biologicals
- (-) Remove Manufacturing filter Manufacturing
- (-) Remove Safety of medicines & medical devices filter Safety of medicines & medical devices
- (-) Remove Blood and blood components filter Blood and blood components
Priority Review pathway for biologicals: feasibility, potential eligibility criteria and determination process
Closed on 28 March 2022
Consultation on potential regulatory options for 'export only' biologicals
Closed on 20 December 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Triptans
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Mometasone
Closed on 17 September 2021
Proposed minor changes to Required Advisory Statements for Medicine Labels (RASML): Chlorhexidine, hydrocortisone, ibuprofen
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Melatonin
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
Closed on 18 May 2021